Cohort study of XELOX in combination with bevacizumab for unresectable or recurrent colorectal cancer
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine X2,000mg/m2, p.o.(day1-14) to be repeated every 3 weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized
创建时间：
2010-04-15
